Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2016; 8(01): 025-029
DOI: 10.4103/0974-2727.176230
Original Article

Serum Total Sialic Acid and Highly Sensitive C-reactive Protein: Prognostic Markers for the Diabetic Nephropathy

Vandana Varma
Department of Biochemistry, M.G.M. Medical College, Indore, Madhya Pradesh, India
,
Meena Varma
Department of Biochemistry, Sri Aurobindo Medical College and PG Institute, Indore, Madhya Pradesh, India
,
Amit Varma
Department of Pathology, Sri Aurobindo Medical College and PG Institute, Indore, Madhya Pradesh, India
,
Ravindra Kumar
Department of Central Research Laboratory, Sri Aurobindo Medical College and PG Institute, Indore, Madhya Pradesh, India
,
Anuradha Bharosay
Department of Biochemistry, Chirayu Medical College, Bhopal, Madhya Pradesh, India
,
Savita Vyas
Department of Pharmocology, M.G.M. Medical College, Indore, Madhya Pradesh, India
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
  PDF Download Permissions and Reprints

ABSTRACT

Background: This study was undertaken to evaluate and establish the role of total sialic acid (TSA) and highly sensitive C-reactive protein (hs-CRP) in type 2 diabetes mellitus (T2DM) and its correlation with complications such as diabetic nephropathy.

Materials and Methods: One hundred fifty-seven patients with T2DM with nephropathy (DN) and 162 patients of T2DM without nephropathy (DM) along with 165 unrelated age and sex-matched healthy controls were included in the study. Serum glucose (fasting and postprandial) levels, renal profile, and lipid profile were done as per standard protocol. Serum TSA test levels and hs-CRP level were evaluated using thiobarbituric acid assay and immunoturbidimetric method respectively.

Results: We observed a higher concentration of serum TSA (82.67 ± 6.63 mg/dl) and hs-CRP (3.2 ± 1.44 mg/L) in diabetic nephropathy than the diabetes mellitus group (73.83 ± 6.90 mg/dl and 2.07 ± 1.32 mg/L, respectively). Both TSA and hs-CRP levels were found significantly correlated with fasting and postprandial blood sugar, hemoglobin A1c, and urine microalbumin levels in both DM and DN groups. Multinomial logistic regression analysis showed that both TSA and hs-CRP was independently associated with diabetic nephropathy.

Conclusion: High serum TSA and hs-CRP levels may increase the microangiopathic (diabetic nephropathy) complications of T2DM.

Key words

Diabetic nephropathy - highly sensitive C-reactive protein - total sialic acid - type 2 diabetes mellitus


Publication History

Article published online:
19 April 2020

© 2016.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011;378:31-40.
  • 2 World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva: World Health Organization; 2011.
  • 3 World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. (WHO/NCD/NCS/99.2). Geneva: World Health Organization; 1999.
  • 4 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35:S64-71.
  • 5 Kumar R, Sharma RK, Agarwal S. Genetic predisposition for development of nephropathy in type 2 diabetes mellitus. Biochem Genet 2013;51:865-75.
  • 6 Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2003;52:1799-805.
  • 7 Martha RM, Fernando GR. Increased levels of CRP in non-controlled type II diabetic subjects. J Diabetes Complications 1999;13:211-5.
  • 8 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
  • 9 Mahajan A, Tabassum R, Chavali S, Dwivedi OP, Bharadwaj M, Tandon N, et al. High-sensitivity C-reactive protein levels and type 2 diabetes in urban North Indians. J Clin Endocrinol Metab 2009;94:2123-7.
  • 10 Shahid HS, Kurdi MI, Zohair AA. Serum high-sensitivity C-reactive protein and lipoprotein (a) levels: A comparison between diabetic and non-diabetic patients with coronary artery disease. Med J Malaysia 2011;66:113-6.
  • 11 Kishore BK, Gejyo F, Arakawa M. Altered glycosylation and sialylation of serum proteins and lipid bound sialic acids in chronic renal failure. Postgrad Med J 1983;59:551-5.
  • 12 Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
  • 13 Chen J, Gall MA, Yokoyama H, Jensen JS, Deckert M, Parving HH. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care 1996;19:130-4.
  • 14 Nayak SB, Bhaktha G. Relationship between sialic acid and metabolic variables in Indian type 2 diabetic patients. Lipids Health Dis 2005;4:15.
  • 15 Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem 1959;234:1971-5.
  • 16 Lima LM, Carvalho MD, Soares AL, Sabino Ade P, Fernandes AP, Novelli BA, et al. High-sensitivity C-reactive protein in subjects with type 2 diabetes mellitus and/or high blood pressure. Arq Bras Endocrinol Metabol 2007;51:956-60.
  • 17 Amanullah S, Jarari A, Govindan M, Basha MI, Khatheeja S. Association of hs-CRP with diabetic and non-diabetic individuals. Jordan J Biol Sci 2010;3:7-12.
  • 18 Chiriboga DE, Ma Y, Li W, Stanek EJ 3rd, Hébert JR, Merriam PA, et al. Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: A longitudinal study. Clin Chem 2009;55:313-21.
  • 19 Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: The Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:3071-8.
  • 20 Pfützner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006;8:28-36.
  • 21 KP, Kumar JA, Rai S, Shetty SK, Rai T, Shrinidhi, et al. Predictive value of serum sialic Acid in type-2 diabetes mellitus and its complication (nephropathy). J Clin Diagn Res 2013;7:2435-7.
  • 22 Masuda H, Wakabayashi R, Wakabayashi I. Serum sialic acid and ankle versus brachial arterial-pressure ratio in NIDDM. Scand J Clin Lab Invest 1998;58:433-39.
  • 23 Crook M, Lumb P, Andrews V, Swaminathan R. Serum total sialic acid, a reputed cardiovascular risk factor, and its relationship to lipids, plasma fasting insulin, blood pressure and body mass index in normal individuals. Clin Sci (Lond) 1998;95:53-7.
  • 24 Krishnamurthy U, Halyal SS, Murthy DS. Serum sialic acid and microalbuminuria in non-insulin dependent diabetes mellitus. Biomed Res 2011;22:31-4.
  • 25 Shahid SM, Mahboob T. Clinical correlation between frequent risk factors of diabetic nephropathy and serum sialic acid. Int J Diabetes Metab 2006;14:138-42.